Amicus Therapeutics, a biopharmaceutical company that develops therapies for rare and orphan diseases, has strengthened its executive leadership with the appointment of two new senior members of the commercial and executive team. Mark Baldry, a biopharmaceutical brand strategist with senior-level experience at Biogen and Shire has joined the company as vice president of global marketing. Willem van Weperen, most recently the former chief commercial officer of Prosensa Holding, has been app...